Drug Trial Radar · NCT04294160
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Dec 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
122
Actual
Start
Jul 22, 2020
Primary completion
Sep 25, 2024
Study completion Sep 25, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 3, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase Ib, open-label platform study of select drug combinations chosen in order to characterize safety and tolerability of each treatment arm tested and to identify recommended doses and regimens for future studies.
Conditions
- BRAF V600 Colorectal Cancer
Interventions
DabrafenibDrug
Capsule for oral use
LTT462Drug
Capsule for oral use
TrametinibDrug
Tablet for oral use
LXH254Drug
Tablet for oral use
TNO155Drug
Capsule for oral use
SpartalizumabBiological
Liquid in vial (Concentrate for solution for infusion) for intravenous use
TislelizumabBiological
Liquid in vial (Concentrate for solution for infusion) for intravenous use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and nature of dose limiting toxicities (DLTs) in the first cycleTime frame: 30 months
- Incidence and severity of AEs and SAEs, including changes in laboratory values, vital signs, and ECGsTime frame: 34 months
- Frequency of dose interruptionsTime frame: 30 months
- Frequency of dose reductionsTime frame: 30 months
- Dose intensityTime frame: 30 months
Locations
18 sites in 10 countries. Site status is shown where the registry gives one.
University of California LA Santa Monica Location
Los Angeles, California
Massachusetts General Hospital Massachusetts General Hospital
Boston, Massachusetts
Sarah Cannon Research Institute SC
Nashville, Tennessee
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas
Novartis Investigative Site
Westmead, New South Wales, Australia
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Ulm, Germany
Novartis Investigative Site
Tel Aviv, Israel
Novartis Investigative Site
Zoetermeer, Netherlands
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Valencia, Valencia, Spain
Novartis Investigative Site
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.